CA2979527A1 - Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease - Google Patents
Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating diseaseInfo
- Publication number
- CA2979527A1 CA2979527A1 CA2979527A CA2979527A CA2979527A1 CA 2979527 A1 CA2979527 A1 CA 2979527A1 CA 2979527 A CA2979527 A CA 2979527A CA 2979527 A CA2979527 A CA 2979527A CA 2979527 A1 CA2979527 A1 CA 2979527A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- alkenyl
- alkynyl
- cycloalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2015/020397 WO2016148674A1 (en) | 2015-03-13 | 2015-03-13 | Conjugates for treating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2979527A1 true CA2979527A1 (en) | 2016-09-22 |
Family
ID=56920017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2979527A Pending CA2979527A1 (en) | 2015-03-13 | 2015-03-13 | Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10624972B2 (https=) |
| EP (1) | EP3268046A4 (https=) |
| JP (1) | JP6676650B2 (https=) |
| CN (1) | CN107847609A (https=) |
| CA (1) | CA2979527A1 (https=) |
| WO (1) | WO2016148674A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170266303A1 (en) * | 2014-11-25 | 2017-09-21 | Endocyte, Inc. | Methods of treating cancer by targeting tumor-associated macrophages |
| JP6676650B2 (ja) | 2015-03-13 | 2020-04-08 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 疾患を処置するためのコンジュゲート |
| US20200323991A1 (en) * | 2016-03-29 | 2020-10-15 | Endocyte, Inc. | Pbd conjugates for treating diseases |
| WO2017205661A1 (en) * | 2016-05-25 | 2017-11-30 | Purdue Research Foundation | Method of treating cancer by targeting myeloid-derived suppressor cells |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| WO2021137646A1 (ko) | 2019-12-31 | 2021-07-08 | 주식회사 레고켐바이오사이언스 | 피롤로벤조디아제핀 유도체 및 이의 리간드-링커 접합체 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60255789A (ja) | 1984-06-01 | 1985-12-17 | Kyowa Hakko Kogyo Co Ltd | マイトマイシン誘導体，その製造法および抗腫瘍剤 |
| CA2044590A1 (en) | 1989-11-13 | 1991-05-14 | Marc D. Better | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO1992003569A1 (en) | 1990-08-29 | 1992-03-05 | Centre Hospitalier Regional De Nantes | Protein polyligands joined to a stable protein core |
| AUPN449295A0 (en) * | 1995-07-28 | 1995-08-24 | Inner And Eastern Health Care Network, The | Radioprotectors |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| US6822086B1 (en) | 1999-08-09 | 2004-11-23 | The General Hospital Corporation | Drug-carrier complexes and methods of use thereof |
| JP4813712B2 (ja) * | 1999-08-09 | 2011-11-09 | ザ ジェネラル ホスピタル コーポレーション | 薬物−担体複合体およびその使用方法 |
| DK1592457T3 (da) | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
| AU2006279304A1 (en) * | 2005-08-19 | 2007-02-22 | Endocyte, Inc. | Multi-drug ligand conjugates |
| CN101287500A (zh) * | 2005-08-19 | 2008-10-15 | 恩多塞特公司 | 多药物配体缀合物 |
| WO2008098368A1 (en) | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim International Gmbh | Inhibitors of hepatitis c ns3 protease |
| BRPI0812970A2 (pt) * | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
| US20100074863A1 (en) * | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
| AU2009293140A1 (en) | 2008-09-17 | 2010-03-25 | Endocyte, Inc. | Folate receptor binding conjugates of antifolates |
| DK2528625T3 (da) * | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| CA2799391A1 (en) | 2010-05-19 | 2011-12-04 | Endocyte, Inc. | Improved process for a folate-targeted agent |
| JP6049642B2 (ja) * | 2011-02-15 | 2016-12-21 | イミュノジェン・インコーポレーテッド | 複合体の調製方法 |
| US20130267522A1 (en) * | 2012-03-01 | 2013-10-10 | Endocyte, Inc. | Methods for treating cancer |
| EP2908818A4 (en) * | 2012-10-16 | 2016-07-13 | Endocyte Inc | CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE |
| BR112015011118B1 (pt) * | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| US10131682B2 (en) * | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| LT3191135T (lt) | 2014-09-12 | 2020-11-25 | Genentech, Inc. | Anti-her2 antikūnai ir imunokonjugatai |
| US20170266303A1 (en) | 2014-11-25 | 2017-09-21 | Endocyte, Inc. | Methods of treating cancer by targeting tumor-associated macrophages |
| JP6676650B2 (ja) | 2015-03-13 | 2020-04-08 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 疾患を処置するためのコンジュゲート |
| US20200323991A1 (en) | 2016-03-29 | 2020-10-15 | Endocyte, Inc. | Pbd conjugates for treating diseases |
-
2015
- 2015-03-13 JP JP2017548170A patent/JP6676650B2/ja active Active
- 2015-03-13 CN CN201580079950.0A patent/CN107847609A/zh active Pending
- 2015-03-13 CA CA2979527A patent/CA2979527A1/en active Pending
- 2015-03-13 EP EP15885705.2A patent/EP3268046A4/en not_active Withdrawn
- 2015-03-13 WO PCT/US2015/020397 patent/WO2016148674A1/en not_active Ceased
- 2015-03-13 US US15/557,703 patent/US10624972B2/en active Active
-
2020
- 2020-03-20 US US16/825,566 patent/US20200289659A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016148674A1 (en) | 2016-09-22 |
| JP6676650B2 (ja) | 2020-04-08 |
| EP3268046A4 (en) | 2018-11-21 |
| CN107847609A (zh) | 2018-03-27 |
| EP3268046A1 (en) | 2018-01-17 |
| US10624972B2 (en) | 2020-04-21 |
| US20200289659A1 (en) | 2020-09-17 |
| US20180228914A1 (en) | 2018-08-16 |
| JP2018509424A (ja) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI440641B (zh) | 蛋白酶體抑制劑 | |
| AU2023203341A1 (en) | Silicon based drug conjugates and methods of using same | |
| US20200289659A1 (en) | Conjugates for treating diseases | |
| CA3026651A1 (en) | Silanol based therapeutic payloads | |
| US11484600B2 (en) | Intermediate drug with synergistic anticancer activity and polyethylene glycol-coupled synergistic anticancer drug, and preparation method therefor and use thereof | |
| CZ20023330A3 (cs) | Konjugáty kamptotecinu a polyglutamové kyseliny a způsoby přípravy | |
| WO2010045598A2 (en) | Psma binding ligand-linker conjugates and methods for using | |
| US20200323991A1 (en) | Pbd conjugates for treating diseases | |
| WO2016168471A1 (en) | Dual disulfide drug conjugates | |
| KR20030096226A (ko) | 개선된 세포간 전달을 보이는 디옥소란 동족체 | |
| US10500286B2 (en) | CCK2R-drug conjugates | |
| WO2016089879A1 (en) | Conjugates of garftase inhibitors | |
| WO2021051720A1 (zh) | 一类抗人egfr抗体药物偶联物及其制备方法与应用 | |
| JP2021006550A (ja) | 炎症の治療のための抗葉酸剤結合体 | |
| US20160303251A1 (en) | Conjugates of garftase inhibitors | |
| CN115974849B (zh) | 一种吲哚氧乙酰胺类衍生物、包含其的药物组合物及其应用 | |
| US20180125992A1 (en) | Drug delivery conjugates of tertiary amine containing drugs | |
| JP2014509613A (ja) | Ｄ−イソグルタミル−［ｄ／ｌ］−トリプトファンのプロドラッグ | |
| JP2020117509A (ja) | 疾患を処置するためのコンジュゲート | |
| WO2015069766A1 (en) | Dupa-indenoisoquinoline conjugates | |
| RU2819399C2 (ru) | Пептиды и фармацевтические композиции для лечения глазных болезней | |
| TW202325273A (zh) | 靶向fap之中子捕獲劑及與其相關之用途及調配物 | |
| KR20260028651A (ko) | 엽산-약물 접합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200311 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20240913 |
|
| N11 | Application terminated |
Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE Effective date: 20250915 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251229 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260105 |